Fludarabine treatment of low grade lymphoid neoplasms refractory to treatment or in relapse;Tratamiento con fludarabina de neoplasias linfoides de bajo grado de malignidad resistentes al tratamiento o en recaida

Medicina Clinica

Volumn 107, Issue 3, 1996, Pages 86-89

  Briones, Javier ^a,c   Montserrat, Emilio ^a   Urbano Ispizua, Alvaro ^a   Esteve, Jordi ^a   Colomer, Dolors ^a   López Guillermo, Armando ^a   Bosch, Francesc ^a   Hadjieu, Eugeni ^a,b   Rozman, Ciril ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; PNEUMONIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VIDARABINE;

EID: 0030012382     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Montserrat E. Tratamiento de los linfomas no hodgkinianos. Med Clin (Barc) 1990; 95: 743-752.
2. Martinez-Francés A, López-Guillermo A, Esteve J, Bosch F, Terol MJ, Montserrat E. Características de los pacientes con linfoma de bajo grado de malignidad y larga supervivencia. Sangre 1995; 40: 53-57.
3. Horning SJ. Treatment approaches to the low-grade lymphomas, Blood 1994; 83: 881-884.
4. Cheson BD. The purine analogs: a therapeutic beauty contest [editorial]. J Clin Oncol 1992; 10: 352-355.
5. Cheson BD. Chronic lymphocytic leukemia and hairy-cell leukemia. Curr Opin Hematol 1994; I: 268-277.
6. Keating MJ, O'Brien S, Plunkett W, Robertson LE. Gandhi V, Estey E. Fludarabine phosphate: a new active agent in hematologic malignancies. Sernin Hematol 1994; 31: 28-39.
7. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B. Fludarabine: a new agent with major activity against chronic lyinpn̈ocylic leukemia. Blood 1989; 74: 19-25.
8. Hochster HS, Kim K, Green MD, Mann RB, Neiman RS, Oken MM. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group Study. J Clin Oncol 1992; 10: 28-32.
9. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-794.
10. Whelan JS, Ganjoo R, Johnson PWM, Rohatiner AZS, Lister TA. Treatment of low-grade non-Hodgkin's lymphoma with fludarabine. Leuk Lymphoma 1993; 10 (Supl): 35-37.
11. O'Brien MER, Matutes E, Cunningham D, Hill M, Emmet E, Ellis PA. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma 1994; 10 (Supl 2). 17-24.
12. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiano M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 7: 81-89.
14. Deane M, Norton JD. Detection of immunoglobulin gene rearrangement in B cell neoplasias by polymerase chain reaction gene amplification. Leuk Lymphoma 1991; 5: 9-22.
15. Vuiller F, Claisse JF, Vandelvelde C, Travade PH, Magnac C, Chevret S. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7: 195-204.
16. Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freeman G. All advanced non-Hodg-kin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3.275-3.280.
17. Cervantes F, Salgado C, Montserrat E, Rozman C. Fludarabine for prolymphocitic leukemia and risk of interstitial pneumonitis lcartal. Lancet 1990; 2: 1.130.
18. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 1990; 17 (Supl 8): 49-62.
19. Cheson BD. Chronic lymphocytic leukemia and hairy-cell leukemia. Curr Opin Hematol 1994; 1: 268-277.
20. Hochster H, Cassileth P. Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol 1990; 17 (Supl 8): 63-65.
21. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 1994; 14 (Supl 2): 11-16.
22. Zinzani PL, Tosi P, Visani G, Martinelli G, Farabegol. P, Buzzi M. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301-306.
23. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl fluoroadenine. Blood 1993; 81: 143-150.
24. Zinzani PL, Lauria F, Rondelli D, Benfenati D, Raspadori D, Bocchia M. Fludarabine in patients with advanced and/or resistant B chronic lymphocytic leukemia. Eur J Haematol 1993; 51: 93-97.
25. Gillis S, Dann FJ, Cass Y, Rochlemer R, Polliack A. Activity of fludarabine in refractory chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma: the Jerusalem experience. Leuk Lymphoma 1994; 15: 173-175.
26. Herrero M, Cabrera JR, Briz M, Forés R, Díez JL, Regidor C. Tratamiento con fludarabina de la leucemia linfática crónica refractaria. Sangre 1995: 40: 115-119.
27. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C. Long term follow up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2.878-2.884.
28. Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol 1995; 6: 219-235.
29. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey C. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1.695-1.700.
30. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1.580-1.589.
31. Robertson LE, Huh YO, Butler JJ, Puph WC, Hirsch-Ginsbery C, Stars S. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic and molecular analysis. Blood 1992; 80: 29-36.
32. Richardson DS, Johnson SA, Hopkins JA, Howe D, Phillips M. Absence of minimal residual disease detectable by FACS, southern blot or PCR in patients with chronic lymphocytic leukemia treated with fludarabine. Acta Oncol 1994; 33: 627-630.
33. Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR. Chemosensitivity of lymphocytes from patients with B- chronic lymphocytic leukemia to chlorambucil, fludarabine and camptothecin analogs. Blood 1994; 84: 3.440-3.446.
34. Lo Coco F, Gaidano G, Lonie D, Offit K, Chaganti R, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2.289-2.295.
35. Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V. Fludarabine: present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 1994; 5 (Supl 2): 79-83.
36. Annaisie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating MJ. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117: 466-469.
37. Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson LB. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 11: 63-68.
38. Hiddemann W, Johnson S, Smith A, Björkholm M, Löffler H, Wylde P. (Multinational CLL Cooperative Group). Fludarabine versus cyclophosphamide, adriamycin, prednisone (CAP) for the treatment of chronic lymphocytic leukemia: results of a multinational prospective randomized trials [resumen]. Blood 1993; 82 (Supl 1): 199.
39. French Cooperative Group on CLL. Comparison of fludarabine (FDB), CAP and CHOP in previously untreated stage B and C chronic lymphocytic leukemia: first interim results of a randomized clinical trial in 247 patients [resumen]. Blood 1994; 84 (Supl 1): 461.